EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:231683 - Anakinra
| ChEBI ID | CHEBI:231683 |
| ChEBI Name | Anakinra |
| Stars | |
| Definition | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the E. Coli bacterial expression system. On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively. A few studies have evaluated the use of anakinra for the treatment of coronavirus disease 2019 (COVID-19). On November 8, 2022, the FDA issued an emergency use authorization (EUA) of anakinra for the treatment of COVID-19 in hospitalized patients who are at risk of progressing to severe respiratory failure. (DrugBank) |
| Submitter | amillett1 |
| Roles Classification |
|---|
| Biological Roles: | antimicrobial agent A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antiviral agent A substance that destroys or inhibits replication of viruses. anti-HIV agent An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. anticoronaviral agent Any antiviral agent which inhibits the activity of coronaviruses. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. |
| Applications: | antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. anti-asthmatic agent Any compound that has anti-asthmatic effects. antiinfective agent A substance used in the prophylaxis or therapy of infectious diseases. antirheumatic drug A drug used to treat rheumatoid arthritis. neuroprotective agent Any compound that can be used for the treatment of neurodegenerative disorders. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. hypoglycemic agent A drug which lowers the blood glucose level. hyperglycemic agent A drug which increases the blood glucose level. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. ophthalmology drug Any compound used for the treatment of eye conditions or eye diseases. dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. gout suppressant A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| Anakinra (CHEBI:231683) has role analgesic (CHEBI:35480) |
| Anakinra (CHEBI:231683) has role anti-asthmatic agent (CHEBI:65023) |
| Anakinra (CHEBI:231683) has role anti-HIV agent (CHEBI:64946) |
| Anakinra (CHEBI:231683) has role anticoronaviral agent (CHEBI:149553) |
| Anakinra (CHEBI:231683) has role antihypertensive agent (CHEBI:35674) |
| Anakinra (CHEBI:231683) has role antiinfective agent (CHEBI:35441) |
| Anakinra (CHEBI:231683) has role antimicrobial agent (CHEBI:33281) |
| Anakinra (CHEBI:231683) has role antineoplastic agent (CHEBI:35610) |
| Anakinra (CHEBI:231683) has role antirheumatic drug (CHEBI:35842) |
| Anakinra (CHEBI:231683) has role antiviral agent (CHEBI:22587) |
| Anakinra (CHEBI:231683) has role cardiovascular drug (CHEBI:35554) |
| Anakinra (CHEBI:231683) has role dermatologic drug (CHEBI:50177) |
| Anakinra (CHEBI:231683) has role gout suppressant (CHEBI:35845) |
| Anakinra (CHEBI:231683) has role hyperglycemic agent (CHEBI:76916) |
| Anakinra (CHEBI:231683) has role hypoglycemic agent (CHEBI:35526) |
| Anakinra (CHEBI:231683) has role immunosuppressive agent (CHEBI:35705) |
| Anakinra (CHEBI:231683) has role neuroprotective agent (CHEBI:63726) |
| Anakinra (CHEBI:231683) has role ophthalmology drug (CHEBI:66981) |
| Anakinra (CHEBI:231683) is a organic molecular entity (CHEBI:50860) |
| Synonyms | Source |
|---|---|
| Alta-2530 | ChEMBL |
| Alta2530 | ChEMBL |
| AMG-719 | ChEMBL |
| Anakinra | ChEMBL |
| Interleukin-1 receptor antagonist anakinra | ChEMBL |
| Osp-101 | ChEMBL |
| Brand Names | Source |
|---|---|
| Antril | ChEMBL |
| Kineret | ChEMBL |
| Registry Numbers | Sources |
|---|---|
| CAS:143090-92-0 | SUBMITTER |